|
Jan 9
|
Moderna (MRNA) Issues 2023 Preliminary Results, Stock Up 4%
|
|
Jan 2
|
MeiraGTx (MGTX) Stock Surges 35% in a Month: Here's Why
|
|
Dec 21
|
CytomX Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 6
|
Pfizer (PFE), Arvinas Post Upbeat Data From Breast Cancer Study
|
|
Dec 5
|
Alterity (ATHE) Up on Preclinical Parkinson's Treatment Data
|
|
Dec 5
|
CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline
|
|
Dec 5
|
Vanda (VNDA) Rises as FDA Accepts NDA for Gastroparesis Drug
|
|
Dec 1
|
AstraZeneca (AZN) to Discontinue Two Studies on Lokelma
|
|
Dec 1
|
Annovis Bio (ANVS) Stock Surges 38% in a Month: Here's Why
|
|
Nov 30
|
AbbVie (ABBV) Posts Encouraging Data From Lung Cancer Study
|
|
Nov 30
|
Adaptimmune (ADAP) Rises as GSK Transfers T-Cell Therapy IND
|
|
Nov 29
|
Emergent (EBS) Gets $75M BARDA Contract for Anthrax Vaccine
|
|
Nov 29
|
Immunovant (IMVT) Up on Positive Initial IMVT-1402 MAD Study Data
|
|
Nov 29
|
SpringWorks (SWTX) Rises on FDA Nod for Desmoid Tumor Drug
|
|
Nov 28
|
Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study
|
|
Nov 28
|
TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug
|
|
Aug 25
|
CytomX Therapeutics (CTMX) Loses -13.45% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
|
|
Apr 27
|
Will CytomX Therapeutics (CTMX) Report Negative Q1 Earnings? What You Should Know
|
|
Apr 25
|
CytomX Therapeutics to Present at the H.C. Wainwright BioConnect Investor Conference at NASDAQ
|